2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Blood Banking, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Devices, Women’s Health, Adverse Events, Biological Processes, Apoptosis, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

2901 Non-invasive optical technique reveals subtype-specific microvascular dysfunction in sickle cell disease

Syed Ahmad S. Ayyubi, MD, Ana Catharina Joaquim, MD2, John K. Tukakira, MBCHB3, Nelly K. Kiriza, MD4, Brian J Philips, PhD5, Christine Saber, MD6, Manzoor Mohideen, PhD7, Jude Jonassaint, RN8, Michele Ly, MD9, Olubusola Oluwole, MD10, Laura M. DeCastro, MD11, Patrick Hines, MD12, Sruti Shiva, PhD13, Enrico M Novelli, MD14, Adam Straub, PhD15, Julia Z Xu, MD, MScGH16
1 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
2 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
3 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
4 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
5 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
6 SUNY Upstate Medical University, Syracuse, New York, United States
7 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
8 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
9 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
10 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
11 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
12 Functional Fluidics, Detroit, Michigan, United States, Wayne State University School of Medicine, Detroit, Michigan, United States
13 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
14 University of Maryland, Baltimore, Maryland, United States
15 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
16 University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Introduction: Chronic hemolysis drives vascular dysfunction in SCD by releasing byproducts that scavenge nitric oxide (NO) and disrupt the NO-soluble guanylyl cyclase pathway, impairing both endothelium-dependent and -independent vasodilation. Noninvasive methods for assessing vascular dysfunction in SCD are limited. Laser speckle contrast imaging (LSCI), combined with microiontophoresis, has been used to show microvascular dysfunction in other chronic vascular conditions, such as coronary artery disease and diabetes but has been rarely used in SCD (Mohan et al. 2010). We characterized endothelium-dependent and -independent vasodilation in individuals with and without SCD and in HbSS and HbSC subtypes.  

Methods: This ongoing prospective, IRB-approved study enrolled participants aged ≥18 years. Patients with SCD in acute pain crises or medical illness, and non-SCD individuals with known cardiovascular disease, diabetes, NSAID use within 7 days, or tobacco, caffeine, alcohol, or illicit drugs within 3 hours of consent were excluded. Acetylcholine (ACh 1%, for endothelium-dependent vasodilation) and sodium nitroprusside (SNP 2.5%, for endothelium-independent vasodilation) were delivered transdermally to the forearm skin microvasculature for 400 seconds by microiontophoresis (PeriIont, Perimed). LSCI (PeriCam PSI, Perimed) was used to measure red cell flux, a surrogate of microvascular blood flow, expressed in relative flux units (RFU). Baseline RFU was measured for 2 minutes (min) prior to drug delivery, and peak RFU (maximal blood flow), ΔRFU (peak minus baseline RFU), time to peak (min to reach peak RFU), and area under the curve (AUC, RFU-min) were used to characterize the vasodilatory effects of ACh and SNP. Statistical analyses were performed using Python. Between-group comparisons used Welch's t-test (n≥30) or Mann-Whitney U (n<30); ACh-versus-SNP comparisons used paired t-tests or Wilcoxon signed-rank tests.

Results: Of 69 enrolled participants, 6 were excluded due to poor data quality, leaving 63 analyzable participants: 37 SCD (20 HbSS, 17 HbSC) and 26 non-SCD (15 HbAA, 11 HbAS). Patients with SCD had higher baseline RFU than non-SCD individuals (p<0.05), indicating increased resting skin microvascular blood flow in SCD. ACh peak RFU (i.e., peak RFU following ACh delivery) and SNP peak RFU were higher in SCD vs. non-SCD (107.7 vs. 95.9, p=0.038; 110.9 vs. 98.4, p=0.087, respectively), in line with the higher SCD baseline RFU. ΔRFU and AUC, which quantify the magnitude of vasodilatory response, were similar for SCD vs. non-SCD for both SNP (ΔRFU = 69.8 vs. 64.2, p=0.42; AUC = 686.5 vs. 636.1, p=0.572) and ACh (ΔRFU = 65.6 vs. 59.5, p=0.116; AUC = 666.7 vs. 577.1, p=0.22)

Among SCD subtypes, HbSS and HbSC had similar baseline RFU and comparable responses to ACh. However, HbSC showed greater response to SNP than HbSS, with higher peak RFU (126.02 vs. 98.13, p=0.003), ΔRFU (82.82 vs. 58.70, p=0.003), and AUC (832.77 vs. 562.08, p=0.017), indicating a more robust endothelium-independent vasodilatory response. Time to peak was significantly longer for SNP than ACh in both subtypes (14.06 vs. 9.82, p<0.001; 14.55 vs. 9.20, p<0.001), consistent with slower endothelium-independent kinetics. The SNP AUC was higher than the ACh AUC in HbSC (832.77 vs. 670.81, p<0.04), but this was reversed in HbSS, with the ACh AUC exceeding the SNP AUC (663.25 vs. 562.08, p=0.024). In absolute terms, the SNP AUC in HbSC was higher than in HbAA (832.8 vs. 707.9, p=0.141), while HbSS was lower than HbAA (AUC 562.1 vs. 701.9, p=0.080).

Conclusions: Patients with SCD have higher baseline microvascular blood flow but show vasodilatory responses to ACh and SNP similar to non-SCD individuals. However, after SCD subtype stratification, HbSC showed greater endothelium-independent vasodilation than HbSS and HbAA, while HbSS had reduced endothelium-independent vasodilation compared to HbAA. HbSS did not demonstrate impaired endothelium-dependent vasodilation, despite its association with hemolysis-induced endothelial damage. These findings highlight the important role of vascular smooth muscle reactivity in SCD vasculopathy and could explain functional differences between HbSS and HbSC. Future directions involve evaluating the relationship between vascular reactivity biomarkers, hemolysis markers, and end-organ complications, supporting the development of a noninvasive optical technique for quantifying microvascular dysfunction in SCD.  

Syed Ahmad S. Ayyubi, MD: No relevant conflicts of interest to declare.